

Lodge with Company Announcements Office and Newstrack, if appropriate, and the Takeover Panel. A copy must also be sent to the company the shares of which are acquired.

Date of disclosure: 10/09/02

DISCLOSURE UNDER RULE 3 OF THE RULES GOVERNING
SUBSTANTIAL ACQUISITIONS OF SHARES ("SARs")

Date of acquisition: 09/09/02

Acquisition in: Pharmagene PLC

(1) Class of voting shares (e.g. ordinary shares)	Number of shares/rights over shares acquired	If rights over shares acquired, as opposed to the shares themselves, specify nature of rights
--	---	---

Ordinary Shares of 5p	575,000 shares N/A rights	N/A
--------------------------	------------------------------	-----

(2) Resultant total holding of voting shares (and % of total voting shares in issue)	Resultant total holding of rights over shares (and % of total voting shares in issue)	Total percentage
8,597,131 (16.39%)	N/A (0.00%)	16.39%

(3) Party making disclosure: Aberforth Partners (as Investment Managers)

(4) (a) Name of person acquiring shares or rights over shares: Aberforth Partners (as Investment Managers) and, if different, beneficial owner: N/A

(b) Names of any other persons acting by agreement or understanding (see SAR 5): N/A

Signed, for and on behalf of the party named in (3) above: N/A

(Also print name of signatory): Gordon R. Young, Partner

Telephone and extension number: 0131 220 0733

Note. Under SAR 5, the holdings of and acquisitions by persons acting by agreement or understanding must be aggregated and treated as a holding of or acquisition by one person. Note 3 on SAR 5 requires persons who must aggregate holdings to disclose certain disposals.

For full details of the SARs disclosure requirements, see Rules 3 and 5 of the SARs. If in doubt, contact the Panel on Takeovers and Mergers, Monitoring Section, Tel. No: 020 7638 0129.